BioFilm Control is a Biotechnology R&D company, formed in 2004, which has developed one-of-a-kind proprietary technology using magnetisable microbeads, protected by 7 patents and 9 trademarks. This technology detects the biofilm behaviour of microorganisms and was automated in 2009. This is the only “biofilm” technology in Medical Analysis Laboratories (Public or Private institutions).
BioFilm Control markets BioFilm Ring Test® and Antibiofilmogram® kits in 96-well plate format for research use only. The Antibiofilmogram® kits study the susceptibility of bacteria to antibiotics, both in planktonic and biofilm populations. Three panels of 11 antibiotics are available, defined for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. Clinical protocols are under way and the first MD-IVD versions with CE marking are scheduled for 2017.
The company also operates its biofilm expertise under R&D (pharmaceutical industry – human health and veterinary applications-, cosmetics industry, food, hygiene, etc).
Beyond microbiology, BioFilm Control can boast the performance of its original technology using magnetisable microbeads in other fields:
– In Immunohaematology to develop blood or total serum diagnosis tests, in less than 45 minutes with no purification steps (detection of malaria parasites, detection of cancerous cells, etc) ;
– In Enzymology, with very high sensitivity for enzymatic mapping (lyases, proteases, lipase, nucleases…) or to characterise enzymatic activities on soluble polymers (with real-time kinetics monitoring of the same sample).
BioFilm Control currently boasts manpower of 10 people working in premises of 400m², 90m² of which dedicated to a P2 laboratory. The team is made up of 2 directors-researchers, one Project Manager, one administrative assistant and 6 technicians. BioFilm Control is also backed by a Scientific Committee made up of: Prof. Kaplan, Ph.D. American University, Washington (inventor of the first antibiofilm agent, Dispersin B), Pr McArthur, M.D., Ph.D., University of Missouri, Kansas City (expert on Mycobacterium tuberculosis, on HIV, on Diagnostic tests), Prof. Tulkens, Univ. Catholique Louvain (one of the founders of EUCAST), Dr Jehl, CHU Strasbourg (Chairman of the French Antibiogram Committee), Dr Laurent, AP-HP Lyon (reference for Bone & Joint Infections), Prof. Lavigne and Prof. Sotto, CHU Nîmes (Diabetic Foot reference)…Read more
Ongoing Antibiofilmogram® validation for clinical diagnosis07/04/2016
Biological validation : A publication in JCM describes the use of the BioFilm Ring Test as a routine analysis method of P. aeruginosa biofilms in case of Cystic Fibrosis. http://jcm.asm.org/content/54/3/657.long Clinical Validation : Lauching of 2 clinical trials, soon followed by a third one. A clinical trial
26th ECCMID Congress , April 9 to 12 , AMSTERDAM , THE NETHERLANDS22/02/2016
BioFilm Control will attend this event and will present a poster showing in particular the use of Antibiofilmogram® test on clinical strains of P. aeruginosa from cystic fibrosis patients. It is shown that some antibiotics conventionally used induce in vitro adhesion of naturally non-adherent strains.
Over 150 m2 of laboratories:
1 P2 laboratory of 90 m2
1 production-dedicated laboratory
1 immunohaematology laboratory
BioFilm Control runs its Hamilton Robotics platform dedicated to :
- microplate preparation (antibiotics, compounds, etc)
- inoculation of bacterial suspensions
- incubation and reading of microplates
Up to 4,000 tests per day in sterile conditions (microbiological safety cabinet, specially designed for the platform)